Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

K Rosenke, Frederick Hansen, Benjamin Schwarz, F Feldmann, Elaine Haddock, R Rosenke, Kent Barbian, Kimberly Meade-White, Atsushi Okumura, Shanna Leventhal, David W. Hawman, Emily Ricotta, Catharine M. Bosio, Craig Martens, Greg Saturday, H Feldmann, Michael A. Jarvis*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Downloads (Pure)

Abstract

<jats:title>Abstract</jats:title><jats:p>The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.</jats:p>
Original languageEnglish
Number of pages0
JournalNature Communications
Volume12
Issue number1
Early online date16 Apr 2021
DOIs
Publication statusPublished - 16 Apr 2021

Fingerprint

Dive into the research topics of 'Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model'. Together they form a unique fingerprint.

Cite this